CytomX Therapeutics, Inc.

CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

CytomX Therapeutics received FDA Fast Track Designation for Varseta-M for the treatment of relapsed/refractory metastatic colorectal cancer. Varseta-M is a potential first-in-class antibody drug conjugate directed toward EpCAM, supported by encouraging Phase 1 data. The company plans to initiate a potential monotherapy registrational study in the first half of 2027 to further evaluate the treatment.

•2mo ago

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CytomX reported Q2 revenue of $1.4 million, down from $18.7 million in the prior year due to the conclusion of collaborations with Bristol Myers Squibb and Astellas, while operating expenses increased to $25.2 million. Despite the revenue decline, the company strengthened its balance sheet with $330.3 million in cash and equivalents, providing a runway into the second half of 2028, supplemented by a $37.0 million payment received from Regeneron in July. Operationally, the Varseta-M program advanced with Phase 1 monotherapy enrollment complete at 113 patients and a registrational study planned for 1H 2027, while the Regeneron alliance expanded to include up to $4.0 billion in potential milestones.

•2mo ago

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

CytomX Therapeutics appointed Dr. Charles Fuchs, M.D., M.P.H., to its Board of Directors, bringing over three decades of experience in oncology research and global drug development. Dr. Fuchs previously served as Chief Medical Officer at Tubulis and held leadership roles at Genentech and Roche, where he led multiple cancer therapies to approval. His expertise is expected to support the advancement of CytomX's PROBODY therapeutic pipeline, particularly the Varseta-M program for metastatic colorectal cancer.

•3mo ago

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CytomX expanded its strategic collaboration with Regeneron to develop conditionally-activated bispecific cancer therapies using CytomX’s PROBODY and Regeneron’s Veloci-Bi platforms. CytomX will receive an immediate $37 million payment for two newly selected targets, with Regeneron securing an option to select up to six additional future targets. The expanded agreement covers potential target nomination, research, development, regulatory, and sales-based milestones totaling approximately $4 billion, plus tiered global net sales royalties for CytomX.

•4mo ago

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

CytomX Therapeutics appointed Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs. Dr. Gokhale brings over 25 years of global regulatory experience, including prior roles at Perspective Therapeutics, Sierra Oncology, Amgen, and the FDA. She will lead regulatory strategy for CytomX’s PROBODY pipeline, specifically supporting the advancement of lead asset Varseta-M toward a potential registrational study in late-line colorectal cancer by the first half of 2027.

•5mo ago